![Erik de Clercq](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Erik de Clercq
Direktor/Vorstandsmitglied bei FermaVir Pharmaceuticals LLC
Aktive Positionen von Erik de Clercq
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
FermaVir Pharmaceuticals LLC
![]() FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Direktor/Vorstandsmitglied | 16.08.2005 | - |
Karriereverlauf von Erik de Clercq
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
FermaVir Pharmaceuticals LLC
![]() FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Health Technology |
- Börse
- Insiders
- Erik de Clercq
- Erfahrung